Enzychem Lifesciences엔지켐생명과학

Enzychem Lifesciences is still loss-making on a trailing basis, with revenue shrinking and a large cash cushion, though its share price has fallen about 9% over the past year.

Enzychem is a Korean biopharma company with drug development, API exports and health food segments, plus a bio-oil subsidiary for renewable fuel feedstock. On trailing twelve-month figures to H1 2026 it reported revenue of ₩69.0B, an operating loss of ₩15.4B and a net loss of ₩18.0B, and it held ₩24.9B in cash against ₩0.7B in borrowings. The share price was ₩990 on 16 October 2026, with a market cap of about ₩83.8B.

What stands out

• Revenue fell 12.4% in 2025 to ₩67.8B, after roughly flat growth in 2024, and the operating margin stayed deeply negative at -21.2%.
• The company posted net losses in every year from 2021 to 2025 in the data, and the trailing net margin is -26.1%.
• Balance sheet looks light on debt: liabilities to equity is 13.1% and borrowings are small relative to cash, though free cash flow was -₩19.2B on a trailing basis.
• Price-to-book is about 0.6 and there is no meaningful earnings multiple because the company is loss-making; the dividend yield is 0%.
• Foreign ownership is 2.8%, unchanged over the last 60 days, and the data has no recent news headlines.
• Recent filings include a 5%+ holding report, a lawsuit filed or ruled item, and an auditor adverse opinion on the half-year review tied to capital impairment or equity under ₩1B.

What to watch

• The half-year filing notes an adverse audit opinion on capital impairment; check the full filing for what it means for equity and listing status.
• Several lawsuit filings appeared in July and September 2026; the data does not say what they concern or their likely outcome.
• The next annual results and any update on cash burn, since free cash flow and losses have been negative in the data provided.